THERAPEUTIC ANTI-FUNGAL NAIL PREPARATION

Abstract: A therapeutic solution and application procedure for curing nail fungus infections or Onychomycosis comprising a combination of an anti-fungal agent with DMSO in an anhydrous solution of Polyglycol, and including a secondary anti-inflammatory agent. The DMSO acts as a delivery vehicle so that active anti-fungal agents such as Miconazole in combination with an anti-inflammatory compound such as ibuprofen can be delivered directly to fungal infected areas under and around the nail. The DMSO, Miconazole, and ibuprofen are dissolved in a viscous solution of Polyglycol so that the combined ingredients may be applied directly to the affected nails with superior penetration. The therapeutic solution is formulated by dissolving the Miconazole into the Polyglycol over heat and dissolving ibuprofen into DMSO over additional heat to form a second, and then combining the two solutions together to form the therapeutic solution. Repeated applications of the resulting solution on Onychomycosis infected nails over one 4-6 week period yields satisfactory result rates as high as 85-90 % without augmenting the therapy with systemic drugs. Most versions of the therapeutic solution are anticipated to not require a prescription.

Description: DESCRIPTION THERAPEUTIC ANTI-FUNGAL NAIL PREPARATION Technical Field The present invention relates generally to therapeutic preparations using the combination of ibuprofen and dimethyl sulfoxide ("DMSO") as a transport mechanism to deliver active agents to infected areas. In particular, the present invention relates to therapeutic preparations using the combination of ibuprofen and DMSO to deliver anti- fungal agents to infected areas relatively inaccessible to conventional therapeutic compounds. Background Art Infections on the exterior of the human body are caused by a variety of microorganisms, including bacteria, fungi, and molds. Many micro-organisms living on or within the body are beneficial, but others multiply rapidly and may form infections if left untreated. Some organisms such as microscopic plants or fungi can live on the skin and obtain nourishment from dead tissues such as hair, nails, and outer skin layers. When fungi growing on the body grows out of control, an infection can result with detrimental effects to living tissue. In addition, fungal infections are communicable and individuals who frequent swimming pools, gyms, shower rooms, and other humid and/or wet environments are susceptible to being infected with various types of fungal infections as other infected individuals visit these public areas. One class of external fungi is Onychomycosis, commonly referred to as "nail fungus." Onychomycosis is an infection of the nail (i.e. unguis) and nail bed caused by pathogenic fungi, among other micro-organisms, and while not life threatening the disease can cause chronic discomfort and embarrassment. The disease attacks the nails and their growth centers making them appear cracked, yellow, and highly disfigured. In acute cases, Onychomycosis can cause the nail to become thick and yellow in color, making it vulnerable to easy damage and from which subungual hemorrhages can result. Onychomycosis is caused by a variety of micro-organisms such as dermatophytes, yeast, and molds. However, the majority of Onychomycosis cases are caused by fungi such as Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, and Epidermophyton floccosum. Once these micro-organisms establish subcutaneous growth, eradication with current over the counter treatment is difficult and reoccurrences of the disease can be costly and time consuming. In recent years Onychomycosis has spread to a higher percentage of adults due, in part, to its contagious nature and the lack of effective medications that can quickly cure the disease once established within the nail bed. Current treatments include long term (3-9 months) application of topical fungicidal creams and/or solutions in combination with systemic fungal treatment drugs such as griseofulvin, terbinafme, and itraconazole. Some of the systemic treatments have undesirable side effects such as nausea, headache, photosensitivity, gastrointestinal intolerance, elevated liver enzymes, and undesirable drug interactions, making the process of eradication difficult and troublesome. It is also noted that systemic fungal treatments are expensive. A treatment program using terbinafme tablets (250mg) can cost over $600.00 and a therapy using itraconazole can cost between $600.00 and $1200.00. Conversely, the instant invention contemplates a non-systemic treatment program costing under $50.00. Part of the difficulty of quickly curing Onychomycosis is the inability to deliver effective anti-fungal agents to the pathogenically active areas such that all of the pathogenic fungus is eradicated. Without full eradication, reoccurrence is likely necessitating a new cycle of combined topical and/or systemic treatments, with the aforementioned systemic effects. Treatment is complicated by the fact that the cutaneous nail shell is not easily penetrated and treatments of infected areas often require thinning of the nail to allow better penetration of anti-fungal agents. The nail acts as a protective barrier under which fungus can grow unhindered and even acts as a vessel for spreading the disease. Current topical anti-fungal ointments and solutions used to treat Onychomycosis do not penetrate in to nail bed easily and tend to leave some portion of the fungus alive after treatment causing reoccurrence of the disease. Heretofore, the medical industry has not produced a topical treatment having the necessary chemical properties to effectively pass through the hard cutaneous nail shell and penetrate into the nail bed for rapid and complete destruction of the fungal infection Therefore, there is a need for a topical solution that quickly and thoroughly penetrates the nail shell, underlying nail bed, and surrounding nail tissue to deliver an effective anti-fungal agent that will kill the causes of Onychomycosis Disclosure of Invention It is the object of the present invention to provide a topical solution containing effective anti-fungal agents that will penetrate the hard cutaneous shell to kill the cause of Onychomycosis A further object of the present invention is to provide a method of making the penetrating topical solution An even further object of the present invention is to provide for a therapeutic treatment procedure for curing Onychomycosis without the advent of systemic drugs In summary, the invention provides for a combination of an anti-fungal agent with combination of ibuprofen and DMSO in an anhydrous solution of polyglycol The combination of ibuprofen and DMSO acts as a delivery vehicle so that active anti-fungal agents such as Miconazole, can be delivered directly to fungal infected areas under and around the nail The Miconazole and lbuprofen/DMSO combination are dissolved in a viscous solution of polyglycol so that the combined ingredients may be applied directly to the affected nails in a topical solution The therapeutic solution is created by dissolving the Miconazole in a portion of the polyglycol until dissolution takes place, dissolving the ibuprofen in the DMSO until dissolution takes place, combining the two liquids, and adding the balance of the polyglycol until the desired volume is reached Repeated applications of the resulting solution on Onychomycosis infected nails over a period of 12-16 weeks yields an 85% to 90% satisfactory result rate without augmenting the topical treatments with systemic drugs Most versions of the preferred solution may be sold over-the-counter and should cost far less than current methods of Onychomycosis eradication Other features and objects and advantages of the present invention will become apparent from a reading of the following descπption Best Mode for Carrying Out the Invention Using DMSO to assist with delivery of chemicals into the blood and tissue is well known. However, use of the combination of ibuprofen and DMSO to deliver anti- fungal agents through and under nail structure has been heretofore unknown In February of 1997, the inventor combined several therapeutic agents with DMSO and conducted expeπmental tπals on human subjects to ascertain the potential for a therapeutic anti-fungal solution and treatment for Onychomycosis The results were surprising, with satisfactory result rates as high as 85-90% after a twelve ( 12) week peπod of treatment, and without systemic drug therapy. In addition, anti-fungal results were seen as early as two weeks after application in some subjects. After subsequent expeπmental tπals m which vaπous ingredient concentrations were tned and after further vaπations m compounding techniques were undertaken, a topical therapeutic solution emerged that has the necessary penetrating charactenstics to cure Onychomycosis. DMSO (sometimes referred to chemically as CH 3 (SO) is a controversial substance having well known solvent properties. A wide range of pπmary pharmacological actions of DMSO have also been documented in laboratory studies such as: membrane transport, anti-inflammation, analgesia, bactπostasis, non-specific enhancement of resistance to bacteria, vasodilation, muscle relaxation, and reduction in serum cholesterol. While the actual mechanism of penetration enhancement is not precisely known (some studies indicate that increased pedicle flap circulation and histamine liberation are causes), DMSO can act as a earner of substances into the body for non-ionized molecules of low molecular weight Studies have also shown that DMSO increases the permeability of the stratum comeum by increasing its water content Some studies indicate that solutions of 90% DMSO (by volume) are more effective as a transport earner than solutions using less than or more than 90% However, clinical tπals using expeπmental versions of the invention show that using a 40%) solution of DMSO provides supenor absorption and earner properties for anti- fungal agents and anti-inflammatoπes. In particular, the combination of Polyglycol 300 MW (molecular weight), ibuprofen USP (U S Pharmacopoeia Standard), and DMSO (99% puπty used at 40%o volume) results in an effective earner for anti-fungal agents such as Miconazole and Clotnmazole Ibuprofen USP [(Chj) 2 ChCh,Ch(Ch 3 COOH)], also known by the trade name Motπn™ is a white crystalline powder with a slight odor which has for some time been known as an anti-inflammatory When ibuprofen is compounded into a 40% by volume polyglycol solution at 4% by volume amounts, delivery of anti-fungal agents into a subcutinal fungus infection is faster than without ibuprofen The exact reason for this is unknown, but the studies have shown that ibuprofen can cause ossification to occur in some forms of human tissue Other anti-mflammatory agents besides ibuprofen well known in the art are suspected of also improving the efficacy of the anti-fungal agent Polyglycol 300 is a viscous, mostly clear solution which is used as an anhydrous base for the invention Polyglycol 300 is supenor as a solution base because it is non- lrπtating, it has a low order of toxicity in human tissue, it is soluble in most organic solvents, and is clear and non-stainmg Furthermore, Polyglycol 300 has viscous properties which allows better retention of the invention on infected areas, such as a nail when applied, thereby improving the dosage volume to infected areas Although several types of anti-fungal agents may be used in the instant invention, one agent Miconazole USP performs well to kill Onychomycosis Miconazole USP (l-[2-(2,4-dιchloraphenyl)-2-[(2,4-dιchloraphenyl) Medthoxyl] ethyl]- lh-imidazole monomtrate, also known by the trade name Monistat™) is a white crystalline powder that has been used as a primary agent in anti-fungal preparations The inventor found that a 4% solution of Miconazole is sufficient to kill the fungi in Onychomycosis when used in a nail penetrating bases Other anti-fungal agents effective in fighting the fungi causing Onychomycosis and suitable for use in the present invention are Clotnmazole, Tioconazole, Nystatin, Terconazole, Butoconazole Nitrate, Unecylemc Acid, Choqumol, Ciclopirox Olamine, Econazole Nitrate, Tπacetm, Tolnaftate, Flucytosine, and Ketoconazole A prefeπed solution embodying the elements of the invention for producing a 100ml quantity contains 4 grams of ibuprofen USP, 40ml of DMSO, 4 grams of Miconazole USP, and 100ml (q.s.) of polyglycol 300MW, NF liquid. To compound the prefeπed solution, measure out (sifting is recommended) 4 grams of Miconazole and warm 40ml of polyglycol in a beaker to 45°C (a temperature range of 40-50°C is satisfactory, but 45°C is optimum). A magnetic stiπer should be employed to facilitate the mixing of ingredients and a temperature of 45°C should be maintained in the beaker until all ingredients have been combined. Slowly add the Miconazole to the polyglycol and let stir until all powder is dissolved. Measure out 40ml of DMSO (99%o pure) and 4 grams of ibuprofen. Add the ibuprofen to the DMSO with stirring and allow all of the powder to dissolve. Add the DMSO/ibuprofen solution to the Miconazole/polyglycol solution with stirring. Add enough polyglycol to the mixture to bring it to a total volume of 100ml. Allow the solution to stir for 15 minutes and then remove the heat source. The resultant solution will have 4% ibuprofen, 40% DMSO, 4% Miconazole. by volume in the polyglycol base. Once the solution reaches room temperature, it may be transferred into holding bottles. To insure the strength and the stability of the invention solution, the above procedure should be followed. For example, Miconazole is insoluble in some liquids, and hence adding it to warmed polyglycol facilitates the dissolution of Miconazole more quickly. Using a different mixing procedure may prevent proper dissolution of the ingredient thereby weakening the solution. Also, ibuprofen should be added to the DMSO to quicken the dissolution process. In order to kill pathogenic micro-organisms living in an infected nail, a periodic application regime using the preferred solution is required. Nails infected with Onychomycosis should be cleaned and washed, and allowed to dry. The solution is then applied liberally to the infected area and all parts of the nail, including the cuticle. The solution is left to air dry directly onto the infected nail. The application procedure should be repeated 3 times a day for twelve weeks, depending on the severity of the infection. A 12 week application of the invention can yield up to a 85-90%) satisfactory result rate in most treatments. Also, the solution can be used against most types of fungi causing Onychomycosis and may be purchased over the counter (according to present Food and Drug Administration guidelines). While I have shown my invention in one form, it will be obvious to those skilled in the art that it is not so limited but it is susceptible of various changes and modifications without departing from the spirit thereof. For example, while the invention teaches a combined solution of DMSO with the anti-fungal agent and ibuprofen, it is contemplated that the anti-fungal agent and anti-inflammatory agents may be combined with polyglycol into a solution which can be applied directly to an affected nail and to which the DMSO may be added directly thereafter. Other such variations embodying the invention are likewise contemplated.

Claims: Claims Having set forth the nature of the present invention, what is claimed is: 1. A topical solution effective in inhibiting the growth of micro-organisms causing Onychomycosis, characterized by: a. a pharmacological agent for killing micro-organisms causing Onychomycosis; b. an anti-inflammatory; c. a polyglycol base into which said agent and said anti-inflammatory are dissolved; and, d. a solution of DMSO mixed with said polyglycol base. 2. A topical solution as recited in claim 1, wherein said pharmacological agent is an antifungal agent selected from the group consisting of Miconazole, Clotrimazole, Tioconazole, Nystatin, Terconazole, Butoconazole Nitrate, Unecylenic Acid, Clioquinol, Ciclopirox Olamine, Econazole Nitrate, Triacetin, Tolnaftate, Flucytosine, and Ketoconazole. 3. A topical solution as recited in claim 2, wherein said anti-inflammatory is ibuprofen. 4. A topical solution as recited in claim 3, wherein said ibuprofen is 4% by volume. 5. A topical solution as recited in claim 2, wherein said polyglycol is characterized by the molecular weight 300. 6. A topical solution as recited in claim 1, wherein said topical solution is characterized by 40% by volume DMSO. 7. A topical solution as recited in claim 1, wherein said pharmacological agent is characterized by between 1-30% by volume of said solution. 8. A topical solution as recited in claim 1, wherein said pharmacological agent is Miconazole. 9. A pharmaceutical composition for enhancing penetration of a pharmaceutically active antifungal substance, characterized by: a. an antifungal agent selected from the group consisting of Miconazole, Clotrimazole, Tioconazole, Nystatin, Terconazole, Butoconazole Nitrate, Unecylenic Acid, Clioquinol, Ciclopirox Olamine, Econazole Nitrate, Triacetin, Tolnaftate, Flucytosine, and Ketoconazole; b. ibuprofen; c. a polyglycol base into which said agent and said ibuprofen are dissolved; and, d. a solution of DMSO mixed with said polyglycol base. 10. A pharmaceutical composition for enhancing penetration of a therapeutic agent through unguis, characterized by: a. means for killing said micro-organisms causing Onychomycosis; b. an anti-inflammatory agent for enhancing efficacy of said killing means; c. an anhydrous base into which said killing means and said anti- inflammatory agent are dissolved; and, d. a solution of DMSO mixed with said anhydrous base for enhancing penetration of said killing means into said unguis. 1 1. A Pharmaceutical composition as recited in claim 10, wherein said anhydrous base is characterized by polyglycol. 12. A method for enhancing transdermal and transcutinel penetration of a pharmaceutically active substance, characterized by: a. from about 1 to 30% by volume of an antifungal agent; b. from about 1 to 40% by volume of ibuprofen; c. from about 10 to 80%> by volume of a polyglycol base into which said agent and said ibuprofen are dissolved; and, d. from about 10 to 80% solution of DMSO mixed with said polyglycol base and in an inverse proportion by volume with said polyglycol base. 13. A method of making a therapeutic solution for inhibiting the growth of micro-organisms causing Onychomycosis, characterized by the steps of: a. heating and maintaining 40 ml of polyglycol liquid at 45° C; b. slowly stirring in 4 grams of Miconazole into said heated polyglycol until dissolved in a first container; c. stirring in adding 4 grams of ibuprofen to 40 ml of 99% pure DMSO liquid until dissolved in a second container; d. combining the solutions in the first and second containers; e. adding additional polyglycol to the combination solution to a desired volume. 14. The method as recited in claim 13, including the additional step of allowing said combined solution to cool to room temperature while stirring until all ingredients are uniform. 15. The method as recited in claim 13, wherein said Miconazole is sifted prior to combining with said heated Polyglycol. 16. The method as recited in claim 14, wherein said method of making a therapeutic solution is characterized by the additional step of filtering said combined solution after said cooling step. 17. The method as recited in claim 13, wherein said step of stirring in Miconazole includes simulaneously adding ibuprofen to a desired level. 18. A method for treating nail fungus, characterized by; a. applying a solution effective in killing Onychomycosis causing microorganisms to a fungus infected nail; b. adding a small quantity of DMSO solution to said Onychomycosis killing solution already applied to said infected nail to enhance penetration of said killing solution through said nail; c. allowing said combined solution from prior steps a-b to air dry; and, d. repeating steps a-c 3-4 times daily for 4-6 weeks. 19. A method of killing micro-organisms causing nail fungus, characterized by the step of applying a solution effective in eliminating fungi comprising: a. an anti-fungal agent selected from the group consisting of Miconazole, Clotrimazole, Tioconazole, Nystatin. Terconazole, Butoconazole Nitrate, Unecylenic Acid, Clioquinol, Ciclopirox Olamine, Econazole Nitrate, Triacetin, Tolnaftate, Flucytosine, and Ketoconazole; b. ibuprofen; c. a polyglycol base into which said agent and said ibuprofen are dissolved; and, d. a solution of DMSO mixed with said polyglycol base. AMENDED CLAIMS [received by the International Bureau on 9 May 2000 (09.05.00); original claims 1-19 replaced by new claims 1-19 (4 pages)] 1. A topical solution effective in inhibiting the growth of micro-organisms causing Onychomycosis, consisting essentially of: a. a pharmacological agent for killing micro-organisms causing Onychomycosis; b. an anti-inflammatory; c. a polyglycol base into which said agent and said anti-inflammatory are dissolved; and, d. a solution of DMSO mixed with said polyglycol base. 2. A topical solution as recited in claim 1 , wherein said pharmacological agent is an antifungal agent selected from the group consisting of Miconazole, Clotrimazole, Tioconazole, Nystatin, Terconazole, Butoconazole Nitrate, Unecylenic Acid, Clioquinol, Ciclopirox Olamine, Econazole Nitrate, Triacetin, Tolnaftate, Flucytosine, and Ketoconazole; 3. A topical solution as recited in claim 2, wherein said anti-inflammatory is ibuprofen. 4. A topical solution as recited in claim 3, wherein said ibuprofen is 4% by volume. 5. A topical solution as recited in claim 2, wherein said polyglycol is of the molecular weight of 300. 6. A topical solution as recited in claim 1 , wherein said topical solution contains 40% by volume DMSO. 7. A topical solution as recited in claim 1 , wherein said pharmacological agent is between l-30%o by volume of said solution. 8. A topical solution as recited in claim 1 , wherein said pharmacological agent is Miconazole. 9. A pharmaceutical composition for enhancing penetration of a pharmaceutically active antifungal substance, consisting essentially of: a. an antifungal agent selected from the group consisting of Miconazole, Clotrimazole, Tioconazole, Nystatin, Terconazole, Butoconazole Nitrate, Unecylenic Acid, Clioquinol, Ciclopirox Olamine, Econazole Nitrate, Triacetin, Tolnaftate, Flucytosine, and Ketoconazole; b. ibuprofen; c. a polyglycol base into which said agent and said ibuprofen are dissolved; and, d. a solution of DMSO mixed with said polyglycol base. 10. A pharmaceutical composition for enhancing penetration of a therapeutic agent through unguis, comprising: a. means for killing said micro-organisms causing Onychomycosis; b. an anti-inflammatory agent for enhancing efficacy of said killing means; c. an anhydrous base into which said killing means and said anti- inflammatory agent are dissolved; and, d. a solution of DMSO mixed with said anhydrous base for enhancing penetration of said killing means into said unguis. 1 1. A Pharmaceutical composition as recited in claim 10, wherein said anhydrous base comprises polyglycol. 12. A composition for enhancing transdermal and transcutinel penetration of a pharmaceutically active substance, consisting essentially of: a. from about 1 to 30% by volume of an antifungal agent; b. from about 1 to 40% by volume of ibuprofen; c. from about 10 to 80% by volume of a polyglycol base into which said agent and said ibuprofen are dissolved; and, d. from about 10 to 80% solution of DMSO mixed with said polyglycol base and in an inverse proportion by volume with said polyglycol base. 13. A method of making a therapeutic solution for inhibiting the growth of micro-organisms causing Onychomycosis, comprising the steps of: a. heating and maintaining 40 ml of Polyglycol liquid at 45° C; b. slowly stirring in 4 grams of Miconazole into said heated Polyglycol until dissolved; c. adding 4 grams of ibuprofen to said Polyglycol and stirring until uniform; d. slowly adding 40 ml of 99% pure DMSO liquid to said Polyglycol; and, e. allowing said solution to cool to room temperature while stirring until all ingredients are uniform. 14. The method as recited in claim 13, wherein said Miconazole is sifted into said heated Polyglycol base. 15. The method as recited in claim 13 , wherein said ibuprofen is sifted into said heated Polyglycol base. 16. The method as recited in claim 13, wherein said method of making a therapeutic solution includes the additional step of filtering said solution after said cooling step. 17. The method as recited in claim 13, wherein said step of stirring in Miconazole comes after said step of adding ibuprofen. 18. A method of killing micro-organisms causing nail fungus, comprising the step of applying a solution effective in eliminating fungi, said solution consisting essentially of: a.an anti-fungal agent selected from the group consisting of Miconazole, Clotrimazole, Tioconazole, Nystatin, Terconazole, Butoconazole Nitrate, Unecylenic Acid, Clioquinol, Ciclopirox Olamine, Econazole Nitrate, Triacetin, Tolnaftate, Flucytosine, and Ketoconazole; b. ibuprofen; c . a polyglycol base into which said agent and said ibuprofen are dissolved; and, d. a solution of DMSO mixed with said polyglycol base. 19. The topical solution of Claim 1 wherein said DMSO solution enables the pharmacological agent to more effectively penetrate the human nail structure to contact and kill said micro-organisms. Statement Under Article 19 Claims 1-19 have been replaced with claims conforming to the amended claims of the U.S. parent application providing a basis for the claimed priority filing date. According to Convention standards, Applicant has supplied replacement pages for the resulting altered claims. The herein submitted amendment was in response to the transmittal of International Search Report date 18 April, 2000. Applicant requests that the submitted amendment be duly entered in file of the above referenced application in anticipation of applicant's filing of a demand for preliminary examination. Should any clarification be needed in the application, Applicant encourages any assigned PCT official to contact the undersigned via telephone. 16 AMENDED SHEET (ARTICLE D)

Inventors: REEVES STANLEY FORREST, REEVES, STANLEY, FORREST
Applicants: ASTAN INC, ASTAN, INC.
Application year: 1999
Main classification: A01N43
IPC codes: A61K9, A61K31, A61K45, A61K47, A61P17, A61P31